Fuzuopali (SHR3162; Fluzoparib; Fuzuloparib) is a potent PARP [poly (ADP-ribose) polymerase] inhibitor with the potential for the treatment of solid tumours. It has been approved in China for recurrent ovarian cancer.

纯度：≥98%

CAS：1358715-18-0